Matt Kapusta, uniQure CEO
June 23, 2022 11:19 AM EDTUpdated 12:51 PM
R&D
Cell/Gene Tx

In trou­bled Hunt­ing­ton’s space, uniQure’s gene ther­a­py shows ear­ly promise

Lei Lei Wu

News Reporter

In ran­dom­ized clin­i­cal tri­al da­ta from a small num­ber of pa­tients, Dutch biotech uniQure shared that its gene ther­a­py for Hunt­ing­ton …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times